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Introduction
Spinal cord injury (SCI) is a highly damaging clinical 
condition with permanent and economic disabilities for 
patients and communities. Traumatic SCI is more prevalent 
in men aged 16–30 years. Therefore, improvement of 
patient’s function after SCI becomes a considerable 
issue in recent decades. Despite the numerous medical 
treatments such as methylprednisolone and thyrotropin-
releasing hormone, the motor and sensory impairments 
persist and have shown limited effectiveness for spinal 
cord recovery.1,2
A promising treatment strategy for injuries to the central 
nervous system is stem cell therapy. The Schwann cell (SC) 
is one of the important components of the peripheral nerve 
cell, that release brain-derived neurotrophic factor and 
provide an appropriate environment for axon renewal.3 
Moreover, bone marrow-derived mesenchymal stem cells 
(MSCs) secrete neuroprotective and immunomodulatory 
cytokines and could differentiate into a variety of cells.4 
The combination of SCs and MSCs are essential to cover 
the mechanisms of spinal cord injuries. Many studies 
have proven the safety of MSC and SC transplantation in 
SCI. However, the results were widely limited.5,6
Few clinical studies have been done to show the possible 
outcomes of combination therapy for the treatment 
of patients with SCI.7,8 In present study, we aimed to 
investigate the effectiveness of co-transplantation of 
autologous bone marrow MSCs and SCs in promoting 
sensory recovery in patients with SCI.
Materials and Methods
Study Design
Five patients (three women and two men) with a mean 
± SD age of 38.80±5.84 years, were enrolled in the study. 
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Among these patients, four patient had cervical and one 
of them had thoracic lesions due to road traffic accidents 
and fall from a height. 
The eligibility criteria for the study was absence of brain 
disease or psychological disorders, no stenosis, tethering 
or compression in magnetic resonance images (MRIs) of 
the spinal cord taken at the beginning of the study. These 
patients were enrolled in our one-year follow-up study. 
All the patients received standard therapy for SCI injury 
such as required spinal surgery and regular rehabilitation 
programs.
During the follow-up course, we evaluated sensory 
changes using the International Standard of Neurological 
Classification for Spinal Cord Injury (ISNCSCI) scoring 
system (motor and sensory), developed by the American 
Spinal Injury Association (ASIA).
Cell Isolation, Characterization, and Transplantation
After the admission of the patients in the operation 
room under standard conditions, cell isolation and 
transplantation of autologous SCs and MSCs were done 
according to the protocol that we used in our previous 
study.9 In order to collect SCs, the sural nerve of the 
person was sliced into 2-mm pieces and incubation 
method was done with collagenase (1.4 U mL−1; Sigma, St. 
Louis, MO, USA) and Dispase (2.4 U mL−1; Sigma). After 
cleaning and washing the collagenase twice with DMEM/
F12 and mesh filtering method, the cells were treated and 
processed with DMEM/F12, without fetal bovine serum 
(FBS) for five days (37°C, 5% CO2). Then, during one 
week the concentration and extraction of FBS (Gibco) 
was increased in the culture to up to 10%. S-100 and P-75 
immunocytological staining was used to characterized 
the separated cells in our study. 
For separating and isolating bone marrow stem 
cells (BMSCs), bone marrow blood (100e150 mL) was 
obtained from the iliac bone. Then, the bone marrow 
blood was centrifuged (400 g for 40 minutes) and the 
mononuclear cell layer was regained from the gradient 
under a compression split by Ficoll (1.077 g/L, Sigma) 
at a range of 1:3. The potency and power of the isolated 
cells were assessed by their capability to differentiate to 
adipogenic and osteogenic cells. 
The MSCs and SCs were cultured separately in 
the environment, and a composition of isolated cells 
composed of MSCs at a final concentration of 1×106 cells 
per mL and SCs at a final concentration and density of 
1×106 cells per mL(total volume of 2 mL) was prepared. 
To transplant cells, patients were hospitalized and 
entered in the course (approximately 2 weeks after 
biopsy). Then, we transplanted the cells into the L4/L5 
level through lumbar puncture using a 24 G spinal needle. 
Results
Cells isolated from the sural nerve were positive for S-100 
and P-75 markers, which indicated that these cells had 
properties of SCs. Also, MSCs were able to differentiate 
to adipogenic and osteogenic cells and were positive for 
CD73, CD90, and CD 105 and negative for CD45 in flow 
cytometry analysis.
Systemic complications such as fever, anaphylactic 
shock, hypersensitivities, rush or inflammation were not 
observed. Infectious complications such as meningitis and 
other complications associated with transplantation were 
absent. All five patients had their regular rehabilitation 
before and after transplantation and we evaluated their 
sensory and motor changes in 6, 12, 18 and 24 months 
after surgery with ASIA scoring system. 
Patient number 1 had grade B ASIA Impairment Scale 
(AIS) in C5 and C6 vertebrae. Before injection, ASIA 
score for sensory system was 16. After transplantation we 
detected sensory change, and, according to our follow-
up, the patient claimed to have improvement in the sense 
of pressure. The second patient had improvement at the 
sensory level after the injection. He had type A AIS before 
injection and his sensory score based on ASIA criteria was 
29 for the right side and 29 for the left side (both sides 
up to T8). Four months later, he improved 11 points on 
each side and reached 40 (L1 sensory level). The third 
patient, who had a type A AIS in the 6th and 7th vertebrae 
of the cervix, had no change in his sensory level. In the 
remaining patients, no progress was found in sensory 
scores according to ISNCSCI criteria (Table 1). We also 
detected paresthesia and muscle spasm in some patient 
after cell injection (Table 2). 
Discussion 
We found that combination of autologous SC and bone 
marrow-derived MSC transplantation could promote 
sensory score in some patients with SCI and there were no 
Table 1. Demographic and Clinical Features of the Patients
Patients Sex Age (y)
Interval Before 
Injection (month)
Cause of Injury Injury Site
Sensory Status Before 
(Right-Left)




1 Female 58 1 (25 d) Accident C5, C6 16-16 56-56 B
2 Male 20 12 Accident T7, T8 29-29 40-40 A
3 Male 55 6 Falling C6, C7 34-34 34-34 A
4 Female 34 3 Accident C8 36-36 36-36 A
5 Female 30 12 Falling C5 28-20 28-20 A
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systemic complications after autologous transplantation.  
Stem cell therapy is an attractive and promising treatment 
strategy for spinal cord regeneration because numerous 
changes occurring in spinal cord tissue after injury, need 
a combination cell therapy to provide axonal regeneration 
promotion and rehabilitation.10 Many trials have been 
performed and applied SCs and MSCs alone for spinal 
cord regeneration.5,11-13 MSCs have an important role 
in cell treatment because of low immunogenicity and 
their ability to differentiate and secrete neuroprotective 
cytokines which can increase neural regeneration.12 SCs 
are able to guide neurite outgrowth, axonal surviving and 
remyelination.14
As mentioned above, recently, combination therapies 
have attracted attention for spinal cord regeneration. 
Although the safety and feasibility of these combination 
has been studied, the results were widely limited.9,15 
Kakabadze and colleagues found improvement of motor 
and sensory functions of various degrees in 50% cases 
after BMSC transplantation and they indicated that the 
transplantation of mononuclear-enriched autologous 
BMSCs is a feasible and safe technique.16 Others reported 
that thirty days after transplantation, 15 patients (75%) 
demonstrated significant improvements in sensory, 
motor, and autonomic nerve func tion.17 
Our results showed that cell transplantation improved 
sensory score in two patients as assessed by the ASIA 
impairment scale. Yazdani and colleagues reported 
that ASIA class in one patient changed from A to B, in 
addition to the improvement in indexes of urodynamic 
study, especially bladder compliance.8
In our study, systemic complications such as fever, 
Anaphylactic shock, hypersensitivities, rush or 
inflammation was not observed which may suggest the 
safety of this cell transplantation. In accordance with our 
results another study indicated that there were no adverse 
findings at least 2 years after autologous transplantation of 
SC and MSCs combination into the injured spinal cord.9
Our study had several limitations. First was the small 
sample size, which might affect the observed correlations. 
Second, further large group studies with control group are 
required to clarify the effect of either cells.  
Conclusion
There were no adverse finding after cell transplantation. 
Also we observed improvement in sensory score in two 
patients. It seems that the use of this combination of cell 
therapy may be effective; but large group studies with 
control group are required to clarify the effect of either 
cells.  
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